These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 15257950

  • 21. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
    de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW, Liver and Thrombosis Study Group.
    Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
    [Abstract] [Full Text] [Related]

  • 22. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
    Alacacioğlu I, Ozcan MA, Alacacioğlu A, Polat M, Yüksel F, Demirkan F, Pişkin O, Ozgenç Y, Ozsan HG, Undar B.
    Thromb Res; 2004 Feb; 114(3):155-9. PubMed ID: 15342211
    [Abstract] [Full Text] [Related]

  • 23. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
    Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Inal V, Aydin HH, Tombuloglu M, Doganavsargil E.
    Thromb Res; 2005 Feb; 115(4):287-92. PubMed ID: 15668188
    [Abstract] [Full Text] [Related]

  • 24. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
    Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A.
    Thromb Haemost; 2000 Sep; 84(3):364-8. PubMed ID: 11019956
    [Abstract] [Full Text] [Related]

  • 25. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 26. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
    Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP.
    Thromb Haemost; 2002 Dec; 88(6):1020-5. PubMed ID: 12529754
    [Abstract] [Full Text] [Related]

  • 27. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A.
    Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
    [Abstract] [Full Text] [Related]

  • 28. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
    Guven GS, Kiliçaslan A, Oz SG, Haznedaroglu IC, Kirazli S, Aslan D, Sözen T.
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
    [Abstract] [Full Text] [Related]

  • 29. Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever.
    Sonmez M, Aydin K, Durmus A, Sucu N, Yilmaz M, Akdogan E, Koksal I, Ovali E, Omay SB.
    J Infect; 2007 Aug; 55(2):184-7. PubMed ID: 17418898
    [Abstract] [Full Text] [Related]

  • 30. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy.
    Watanabe T, Minakami H, Sakata Y, Matsubara S, Sato I, Suzuki M.
    Gynecol Obstet Invest; 2004 Aug; 58(1):19-21. PubMed ID: 15004439
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.
    Danese S, Papa A.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):826-8. PubMed ID: 18794594
    [Abstract] [Full Text] [Related]

  • 34. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
    Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M.
    Transplant Proc; 2006 Sep; 38(1):105-7. PubMed ID: 16504676
    [Abstract] [Full Text] [Related]

  • 35. Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma.
    Balcik OS, Albayrak M, Uyar ME, Dagdas S, Yokus O, Ceran F, Cipil H, Kosar A, Ozet G.
    Blood Coagul Fibrinolysis; 2011 Jun; 22(4):260-3. PubMed ID: 21297448
    [Abstract] [Full Text] [Related]

  • 36. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
    Boffa MB, Koschinsky ML.
    Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
    [Abstract] [Full Text] [Related]

  • 37. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
    Dusse LM, Cooper AJ, Lwaleed BA.
    Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
    [Abstract] [Full Text] [Related]

  • 38. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Mar; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 39. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Kim PY, Foley J, Hsu G, Kim PY, Nesheim ME.
    Anal Biochem; 2008 Jan 01; 372(1):32-40. PubMed ID: 17967438
    [Abstract] [Full Text] [Related]

  • 40. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
    Erdoğan M, Karadeniz M, Alper GE, Tamsel S, Uluer H, Cağlayan O, Saygili F, Yilmaz C.
    Exp Clin Endocrinol Diabetes; 2008 Mar 01; 116(3):143-7. PubMed ID: 18350479
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.